Sunday, April 2, 2023
  • Login
CEO North America
  • Home
  • Business
    • Entrepreneur
    • Industry
    • Innovation
    • Management & Leadership
  • CEO Interviews
  • CEO Life
    • Art & Culture
    • Food
    • Health
    • Travel
    • Environment
  • Opinion
  • News
  • Multimedia
No Result
View All Result
  • Home
  • Business
    • Entrepreneur
    • Industry
    • Innovation
    • Management & Leadership
  • CEO Interviews
  • CEO Life
    • Art & Culture
    • Food
    • Health
    • Travel
    • Environment
  • Opinion
  • News
  • Multimedia
No Result
View All Result
CEO North America
No Result
View All Result

Biogen Names Sanofi Veteran Viehbacher as CEO

in News
Biogen names sanofi veteran viehbacher as ceo
Share on LinkedinShare on WhatsApp

Former Sanofi boss Christopher Viehbacher will become the new CEO of Biogen, the company said Thursday.

The move comes as the Cambridge, Massachusetts firm is struggling after a series of setbacks for Alzheimer’s drug Aduhelm and intense competition for its top-selling multiple sclerosis drugs.

Viehbacher is an industry veteran, most notably serving as Sanofi’s CEO from 2008 to 2014. In a high-profile move eight years ago, Sanofi’s board removed Viehbacher from his post.

Viehbacher will replace Michel Vounatsos, who announced his departure in May. He will step into his role on Nov. 14, Biogen said.

Viehbacher founded private equity firm Gurnet Point Capital after being ousted from French giant Sanofi.

Vounatsos, who became Biogen CEO in 2017, announced his departure after the U.S. government’s Medicare program restricted coverage of Aduhelm to patients in clinical trials. Vounatsos plans to stick around at the biotech firm for a limited period of time to smooth the transition.

“The selection of a new CEO has been front-of-mind for Biogen investors since Mr. Vounatsos’ announced departure,” said analyst Laura Chico.

During his six-year tenure as Sanofi CEO, Viehbacher was instrumental in the company’s $20 billion deal for Genzyme in 2011.

His appointment ends a months-long search for a successor. The company’s shares rose 2.4% to $289.01 in premarket trading.

Tags: BiogenChristopher ViehbacherSanofi

Related Posts

Amazon’s zoox tests robotaxi on public road with employees as passengers
News

Amazon’s Zoox tests robotaxi on public road with employees as passengers

New york regulator orders binance stablecoin backer to stop issuing token
News

New York regulator orders Binance stablecoin backer to stop issuing token

Oil falls on demand fears as fed ‘make or break moment’ approaches
News

Oil falls on demand fears as Fed ‘make or break moment’ approaches

U. S. Consumer prices revised higher in december, november
News

U.S. consumer prices revised higher in December, November

Lyft shares sink after grim forecast shows it falling behind uber
News

Lyft shares sink after grim forecast shows it falling behind Uber

China says proposed u. S. Ban on chinese buying u. S. Property violates market rules
News

China says proposed U.S. ban on Chinese buying U.S. property violates market rules

Yahoo to lay off more than 20% of staff
News

Yahoo to lay off more than 20% of staff

Hyundai in talks with u. S. Labor department over alabama child labor
News

Hyundai in talks with U.S. Labor Department over Alabama child labor

Disney to cut 7,000 jobs in major revamp by ceo iger
News

Disney to cut 7,000 jobs in major revamp by CEO Iger

Elon musk has an active stake in twitter; started buying stock in january
News

Elon Musk to unveil Tesla’s ‘Master Plan 3’ at first investor day

No Result
View All Result

Recent Posts

  • Symbotic’s CEO Rick Cohen shines a light on the consumer goods supply revolution
  • CEO John Wynne outlines how Fortis Solution Group is disrupting the packaging industry
  • CEO Keh-Shew Lu explains how Diodes Inc is pushing the frontiers of connectivity
  • CEO NA Andrea Pirondini explains why the Prysmian Group is best-in-class at cable solutions
  • Eric Clark on how ONE NTT is driving client-led innovation

Recent Comments

    Archives

    Categories

    • Art & Culture
    • Business
    • CEO Interviews
    • CEO Life
    • Editor´s Choice
    • Entrepreneur
    • Environment
    • Food
    • Health
    • Highlights
    • Industry
    • Innovation
    • Issues
    • Management & Leadership
    • Multimedia
    • News
    • Opinion
    • PrimeZone
    • Printed Version
    • Travel
    • Uncategorized

    Meta

    • Log in
    • Entries feed
    • Comments feed
    • WordPress.org

    • CONTACT
    • GENERAL ENQUIRIES
    • ADVERTISING
    • MEDIA KIT
    • DIRECTORY
    • TERMS AND CONDITIONS

    Editorials – stuart.james@ceo-na.com

    Advertising – media@ceo-na.com

    NEW YORK

    110 Wall St.,
    3rd Floor
    New York, NY.
    10005
    USA
    +1 212 432 5800

     

    MEXICO CITY

    Paseo de la Reforma 296,
    Floor 38
    Mexico City
    06600
    MEXICO

    • CONTACT
    • GENERAL ENQUIRIES
    • ADVERTISING
    • MEDIA KIT
    • DIRECTORY
    • TERMS AND CONDITIONS

    Editorials –
    stuart.james@ceo-na.com

    Editor-In-Chief –

    caroline.sposto@ceo-na.com

    Editorials – editorials@ceo-na.com

    Advertising –
    media@ceo-na.com

    NEW YORK

    110 Wall St.,
    3rd Floor
    New York, NY.
    10005
    USA
    +1 212 432 5800

    MEXICO CITY

    Paseo de la Reforma 296,
    Floor 38
    Mexico City
    06600
    MEXICO

    CEO North America © 2022 - Sitemap

    No Result
    View All Result
    • Home
    • Business
      • Entrepreneur
      • Industry
      • Innovation
      • Management & Leadership
    • CEO Interviews
    • CEO Life
      • Art & Culture
      • Food
      • Health
      • Travel
      • Environment
    • Opinion
    • News
    • Multimedia

    © 2023 JNews - Premium WordPress news & magazine theme by Jegtheme.

    Welcome Back!

    Login to your account below

    Forgotten Password?

    Retrieve your password

    Please enter your username or email address to reset your password.

    Log In